Search
for
Sort by
Research 30 of 1000+
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Glycyrrhizic Acid Alleviates Osimertinib‐Induced Cutaneous Toxicity by Inhibiting Keratinocyte Apoptosis and Inflammation
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Cutaneous toxicities of cancer therapy
- Cutaneous toxicities of new treatments for melanoma
- Cutaneous Toxicities From Transplantation-Related Medications
- Network pharmacology-based preventive effect of XZF on cutaneous toxicities induced by EGFR inhibitor
- Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib
- P164 Cutaneous toxicities occurring during amivantamab treatment: the experience of a single large specialist institution
- Kava-induced acute cutaneous toxicity: An increasingly recognized characteristic clinicohistologic pattern
- SUSPECTED CUTANEOUS DRUG TOXICITY IN RHEUMATOID ARTHRITIS—AN EVALUATION
- ORAL TARGETED THERAPY-INDUCED CUTANEOUS TOXICITY: LIFE EXPERIENCE OF PATIENTS WITH ADVANCED LUNG CANCER IN TAIWAN
- Incidence and management of cutaneous toxicities associated with cetuximab
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic/Dermatologic Cooperation
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging
- Cutaneous adverse effects of targeted therapies
- The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
- IMMUNE-RELATED SKIN TOXICITIES TO CHECKPOINT INHIBITORS THERAPY
- Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report
- Dermatological adverse events with taxane chemotherapy
- Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer
- Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib
- Hidradenitis secondary to nirogacestat, a recently approved desmoid tumor medication
- Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
- Androgens in women
- Skin toxicity of anti‐cancer therapy